Measurement of lactate concentration in the cerebrospinal fluid (CSF) is useful for diagnosing an inflammatory response in the central nervous system (CNS); thus, we read the study by Slack et al. 'Cerebrospinal fluid lactate: measurement of an adult reference interval' 1 with great interest.
The KEB can be defined as the theoretical average number of molecules of adenosine triphosphate (ATP) produced from one molecule of glucose under given conditions in the CSF compartment.
By investigating the molar concentrations of glucose and lactate in the CSF and calculating the KEB, we can distinguish three 'energy levels' in the CSF: (1) KEB values >28.0 indicate normal energy conditions in the CSF, but cannot rule out a possible pathological process in the CNS; (2) KEB values 428.0 indicate increased anaerobic metabolism in the CSF, which may be associated with CNS inflammation; (3) KEB values <10.0, including values below 0.0, indicate a very high level of anaerobic metabolism in the CSF, usually related to severe inflammation with an oxidative burst of phagocytes in the CNS. 2, 4, 5 Cytological investigations of the CSF are also of key importance in the diagnosis of CNS impairment. The combination of KEB and CSF cytology enables differentiation between less intense serous inflammations, and severe inflammations caused by an oxidative burst of neutrophil granulocytes or macrophages in the CNS.
The finding of a significant number of CSF neutrophil granulocytes and a high degree of CSF anaerobic metabolism (with KEB values <10.0) is typical of purulent inflammation in the CNS, usually involving extracellular bacteria. 2, 4, 5 Similarly, the finding of a significant number of CSF lymphocytes or monocytesmacrophages and a high degree of anaerobic metabolism in the CSF compartment (KEB values <10.0) may signify an intense inflammatory response in the CNS with an oxidative burst of macrophages, involving intracellular bacteria, mycotic agents or cancer. 2, 5 Thus, our solution is not only to investigate the lactate concentrations in the CSF, but in particular to also determine the extent of anaerobic metabolism in the CSF compartment via the KEB level. 
Insulin analogues as a new example of interference in insulin assays
In a recent article, Dayaldasani et al. 1 carefully assessed cross-reactivity of five insulin analogues in three immunometric insulin assays. An excellent editorial 2 also highlighted this complex phenomenon as a new source of error in immunoassay. Cross-reactivity was assessed by adding appropriate amounts of analogues to serum with known/constant insulin concentrations. Interferences of varying degrees of magnitude were found in each of the three assays.
In the 1950s, insulin (molecular weight 5808 Da) was considered to be non-immunogenic. Porcine and bovine insulins, which differ from human insulin by a single amino acid (porcine) and three amino acids (bovine), respectively, were widely used. Subsequently, such small differences from human insulin were shown to provoke production of endogenous insulin antibodies in some patients. The advent of human recombinant insulin reduced but did not eliminate the immunogenicity problem.
The five insulin analogues listed in the study of Dayaldasani et al. 1 are also structurally different from naturally secreted human insulin. They are engineered recombinant forms in which amino acids in specific locations have been altered. For example, among the listed short-acting analogues, proline is substituted with aspartic acid at position 28 in the B-chain of insulin aspart; in insulin lispro, the penultimate C-terminal lysine and proline residues in the B-chain are reversed; in insulin glulisine there are two substitutions -the asparagine at position 3 in the B-chain is replaced by lysine, and the lysine at position 29 by glutamic acid. Further structural changes are introduced in long-acting analogues. In insulin glargine, the glycine at position 21 on the A-chain is substituted with asparagine, and two arginines are added to the C-terminus of the B-chain, while in insulin detemir, a fatty acid (myristic acid) is linked to the lysine at position 29 on the B-chain.
Interestingly, insulin aspart and porcine insulin, which both differ from human insulin by a single amino acid, have similar immunogenicity. 3, 4 Engineering recombinant forms of insulin analogues was primarily aimed at favourably enhancing their pharmacokinetics (insulin concentration over time) and pharmacodynamics (resulting effects on glucose over time). Immunogenicity was a secondary effect, not necessarily detrimental to insulin action (for example, antibodies binding insulin might prolong its duration of action). In addition to the immunogenicity of insulin analogues, they have the potential to interfere with immunoassays and affect their accuracy. [3] [4] [5] [6] [7] [8] Thus, biochemical investigation of patients treated with insulin analogues must take into account not only their known cross-reactivity in immunoassays as reported 1,2 but also their 'known-unknown' adverse potential, i.e. possible presence of endogenous antibodies and its impact on accuracy. In general, the immunogenicity of a substance is influenced by numerous factors such as its molecular size, chemical
